Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 16/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | AXL | P30530 | 2/20 | 0.34 |
| ▸ | MERTK | Q12866 | 2/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13600209 | 0.85 | MAP4K1 (0.50) | MAP4K1CYP3A4ABL1AXLMERTK | |
| SCHEMBL3489573 | 0.80 | MAP4K1 (0.43) | MAP4K1CYP3A4ABL1AXLMERTK | |
| SCHEMBL3488666 | 0.77 | MAP4K1 (0.57) | MAP4K1CYP3A4ABL1AXLMERTK | |
| SCHEMBL12344591 | 0.76 | MAP4K1 (0.54) | MAP4K1CYP3A4ABL1PIK3C3 | |
| SCHEMBL3489336 | 0.67 | MAP4K1 (0.43) | MAP4K1CYP3A4ABL1AXLMERTK | |
| SCHEMBL31318215 | 0.65 | MAP4K1 (0.69) | MAP4K1CYP3A4ABL1 | |
| SCHEMBL12343385 | 0.63 | MAP4K1 (0.47) | MAP4K1CYP3A4ABL1PIK3C3 | |
| SCHEMBL3488624 | 0.63 | MAP4K1 (0.56) | MAP4K1CYP3A4ABL1 | |
| SCHEMBL13600212 | 0.63 | MAP4K1 (0.54) | MAP4K1CYP3A4ABL1PIK3C3 | |
| SCHEMBL3491882 | 0.63 | MAP4K1 (0.50) | MAP4K1CYP3A4ABL1PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268994-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100036118-A1 | Fused Ring Heterocycle Kinase Modulators | SGX PHARMACEUTICALS, INC. | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036118-A1 | Fused Ring Heterocycle Kinase Modulators | MAP3K20, TTK, MAP3K19 | MAP4K1 19/4885CYP3A4 3559/4885ABL1 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.